LEADER 03125nam  22004935  450 
001 9910300285403321
005 20230831142822.0
010   $a3-319-76879-4
024 7 $a10.1007/978-3-319-76879-3
035   $a(CKB)4100000004831857
035   $a(DE-He213)978-3-319-76879-3
035   $a(MiAaPQ)EBC5419318
035   $a(PPN)229493815
035   $a(EXLCZ)994100000004831857
100   $a20180605d2018      u|         0
101 0 $aeng
135   $aurnn|008mamaa
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aMyelodysplastic Syndromes $eDiagnosis - Prognosis - Therapy /$fedited by Uwe Platzbecker, Pierre Fenaux
205   $a1st ed. 2018.
210  1$aCham :$cSpringer International Publishing :$cImprint: Springer,$d2018.
215   $a1 online resource (V, 157 p. 26 illus., 22 illus. in color.) 
225 1 $aHematologic Malignancies,$x2197-9774
311   $a3-319-76878-6 
327   $aDiagnostics and Prognosis: Morphology and Flow -- Molecular -- Histology -- Clinical Scores -- Chronic Myelomonocytic Leukemia -- Therapy: Erythropoietic Stimulating Agents -- Activin-receptor Modulation -- Iron Chelation -- Immunomodulator Lenalidomide -- Hypomethylating Agents -- Allogeneic Hemotopoietic Stem Cell Transplantation. .
330   $aThis book reviews the standard diagnostic and therapeutic management of patients with myelodysplastic syndromes (MDS) and examines ongoing research developments in the field. The importance of appropriate prognostic stratification, taking into account recent advances in understanding of the molecular pathogenesis of MDS, is explained, and both established and novel treatment approaches are discussed in depth. The coverage includes, for example, the use of erythropoietic stimulating agents, iron chelation therapy, the immunomodulator lenalidomide, hypomethylating agents such as azacitidine, and allogeneic hematopoietic stem cell transplantation. Myelodysplastic syndromes are heterogeneous and complex hematologic disorders ranging from indolent conditions to forms approaching the aggressiveness of acute myeloid leukemia. The diversity of MDS gives rise to challenges in diagnosis and clinical decision making, and the highly variable clinical course necessitates a risk-adapted treatment strategy and the application of disease-specific therapies. Hematologists, oncologists, and other interested clinicians will find this book to be an invaluable source of information on diagnostic and prognostic evaluation and treatment selection.
410  0$aHematologic Malignancies,$x2197-9774
606   $aHematology
606   $aOncology
606   $aHematology
606   $aOncology
615  0$aHematology.
615  0$aOncology.
615 14$aHematology.
615 24$aOncology.
676   $a616.15
702   $aPlatzbecker$b Uwe$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aFenaux$b Pierre$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300285403321
996   $aMyelodysplastic Syndromes$91751096
997   $aUNINA